A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Clinical trial NCT02214225 · COMPLETED

Trial details

NCT number: NCT02214225
Sponsor: Seqirus
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Influenza, Human

Start date: 2014-08-01
Primary completion: 2014-11-01
Enrollment: 3484

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.